- Home
- RDCM vs OBIO Comparison
RDCM vs OBIO Comparison
Compare RDCM & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- OBIO
- Stock Information
- Founded
- RDCM 1985
- OBIO 2017
- Country
- RDCM Israel
- OBIO United States
- Employees
- RDCM N/A
- OBIO N/A
- Industry
- RDCM Computer peripheral equipment
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- RDCM Technology
- OBIO Health Care
- Exchange
- RDCM Nasdaq
- OBIO Nasdaq
- Market Cap
- RDCM 157.9M
- OBIO 156.6M
- IPO Year
- RDCM 1997
- OBIO N/A
- Fundamental
- Price
- RDCM $14.08
- OBIO $5.28
- Analyst Decision
- RDCM Strong Buy
- OBIO Strong Buy
- Analyst Count
- RDCM 2
- OBIO 5
- Target Price
- RDCM $15.00
- OBIO $15.80
- AVG Volume (30 Days)
- RDCM 71.7K
- OBIO 182.8K
- Earning Date
- RDCM 02-12-2025
- OBIO 11-12-2024
- Dividend Yield
- RDCM N/A
- OBIO N/A
- EPS Growth
- RDCM 660.55
- OBIO N/A
- EPS
- RDCM 0.46
- OBIO N/A
- Revenue
- RDCM $58,755,000.00
- OBIO $2,647,000.00
- Revenue This Year
- RDCM $18.92
- OBIO $22.61
- Revenue Next Year
- RDCM $11.27
- OBIO $16.64
- P/E Ratio
- RDCM $30.30
- OBIO N/A
- Revenue Growth
- RDCM 17.80
- OBIO N/A
- 52 Week Low
- RDCM $8.18
- OBIO $3.96
- 52 Week High
- RDCM $14.33
- OBIO $10.06
- Technical
- Relative Strength Index (RSI)
- RDCM 67.92
- OBIO 50.69
- Support Level
- RDCM $11.90
- OBIO $5.00
- Resistance Level
- RDCM $13.37
- OBIO $5.70
- Average True Range (ATR)
- RDCM 0.77
- OBIO 0.57
- MACD
- RDCM 0.19
- OBIO 0.05
- Stochastic Oscillator
- RDCM 90.83
- OBIO 56.41
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.